Patents by Inventor Manuel ELLERMANN
Manuel ELLERMANN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11897867Abstract: The present invention provides 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives of formula (I): The present invention provides 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives of formula (I):Type: GrantFiled: August 2, 2018Date of Patent: February 13, 2024Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc.Inventors: Manuel Ellermann, Timothy Lewis
-
Patent number: 11773070Abstract: The present invention provides dihydrooxydiazinone compounds of general formula (I) in which R1, R2, R3, and R4, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.Type: GrantFiled: July 14, 2022Date of Patent: October 3, 2023Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.Inventors: Manuel Ellermann, Stefan Nikolaus Gradl, Charlotte Christine Kopitz, Martin Lange, Adrian Tersteegen, Philip Lienau, Christa Hegele-Hartung, Detlev Sülzle, Timothy A. Lewis, Heidi Greulich, Xiaoyun Wu, Matthew Meyerson, Alex Burgin
-
Publication number: 20230017200Abstract: The present invention provides dihydrooxydiazinone compounds of general formula (I): in which R1, R2, R3, and R4, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: July 11, 2022Publication date: January 19, 2023Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.Inventors: Manuel ELLERMANN, Stefan Nikolaus GRADL, Charlotte Christine KOPITZ, Martin LANGE, Adrian TERSTEEGEN, Philip LIENAU, Christa HEGELE-HARTUNG, Detlev SÜLZLE, Timothy A. LEWIS, Heidi GREULICH, Xiaoyun WU, Matthew MEYERSON, Alex BURGIN
-
Publication number: 20220396554Abstract: The present invention provides dihydrooxydiazinone compounds of general formula (I) in which R1, R2, R3, and R4, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: July 14, 2022Publication date: December 15, 2022Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.Inventors: Manuel ELLERMANN, Stefan Nikolaus GRADL, Charlotte Christine KOPITZ, Martin LANGE, Adrian TERSTEEGEN, Philip LIENAU, Christa HEGELE-HARTUNG, Detlev SÜLZLE, Timothy A. LEWIS, Heidi GREULICH, Xiaoyun WU, Matthew MEYERSON, Alex BURGIN
-
Patent number: 11427553Abstract: The present invention provides dihydrooxydiazinone compounds of general formula (I): in which R1, R2, R3, and R4, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.Type: GrantFiled: August 2, 2018Date of Patent: August 30, 2022Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.Inventors: Manuel Ellermann, Stefan Nikolaus Gradl, Charlotte Christine Kopitz, Martin Lange, Adrian Tersteegen, Philip Lienau, Christa Hegele-Hartung, Detlev Sülzle, Timothy A. Lewis, Heidi Greulich, Xiaoyun Wu, Matthew Meyerson, Alex Burgin
-
Publication number: 20210353630Abstract: The present invention includes name compounds of general formula (I): (I) in which R1, R2, R3 and R4 are as defined herein, methods for their preparation, pharmaceutical compositions and combinations comprising said compounds, and their use for the treatment of hyperproliferative diseases.Type: ApplicationFiled: July 30, 2021Publication date: November 18, 2021Applicants: BAYER AKTIENGESELLSCHAFT, THE BROAD INSTITUTE, INC.Inventors: Stefan Nikolaus GRADL, Manuel ELLERMANN, Philip LIENAU, Charlotte Christine KOPITZ, Martin LANGE, Adrian TERSTEEGEN, Detlev SÜLZLE, Timothy A. LEWIS, Heidi GREULICH, Xiaoyun WU
-
Patent number: 11142522Abstract: The present invention features improved compounds, especially the compound having the structure (1). Compositions and methods of identifying patients having cancer using biomarkers (e.g., PDE3A, PDE3B, SLFN12 and/or CREB3L1) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention.Type: GrantFiled: February 1, 2018Date of Patent: October 12, 2021Assignees: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., Bayer Aktiengesellschaft, Bayer Pharma AktiengesellschaftInventors: Timothy A. Lewis, Xiaoyun Wu, Heidi Greulich, Matthew Meyerson, Manuel Ellermann, Philip Lienau, Knut Eis, Antje Margret Wengner, Charlotte Christine Kopitz, Martin Lange
-
Publication number: 20200369633Abstract: The present invention provides dihydrooxydiazinone compounds of general formula (I): in which R1, R2, R3, and R4, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: August 2, 2018Publication date: November 26, 2020Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.Inventors: Manuel Ellermann, Stefan Nikolaus Gradl, Charlotte Christine Kopitz, Martin Lange, Adrian Tersteegen, Philip Lienau, Christa Hegele-Hartung, Detlev Sülzle, Timothy A. Lewis, Heidi Greulich, Xiaoyun Wu, Matthew Meyerson, Alex Burgin
-
Publication number: 20200247783Abstract: The present invention provides 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives of formula (I): The present invention provides 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives of formula (I):Type: ApplicationFiled: August 2, 2018Publication date: August 6, 2020Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.Inventors: Manuel Ellermann, Stefan Nikolaus Gradl, Charlotte Christine Kopitz, Martin Lange, Adrian Tersteegen, Philip Lienau, Detlev Sülzle, Timothy Lewis, Heidi Greulich, Xiaoyun Wu, Matthew Meyerson
-
Patent number: 10668071Abstract: The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of menorrhagia, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.Type: GrantFiled: August 10, 2018Date of Patent: June 2, 2020Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Jorma Haßfeld, Tom Kinzel, Johannes Köbberling, Yolanda Cancho-Grande, Kristin Beyer, Susanne Röhrig, Maria Köllnberger, Michael Sperzel, Nils Burkhardt, Karl-Heinz Schlemmer, Christian Stegmann, Joachim Schuhmacher, Matthias Werner, Manuel Ellermann
-
Publication number: 20200062741Abstract: The present invention features improved compounds, especially the compound having the structure (1). Compositions and methods of identifying patients having cancer using biomarkers (e.g., PDE3A, PDE3B, SLFN12 and/or CREB3L1) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention.Type: ApplicationFiled: February 1, 2018Publication date: February 27, 2020Applicants: THE BROAD INSTITUTE, INC., DANA-FARBER CANCER INSTITUTE, INC., BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGESELLSCHAFTInventors: TIMOTHY A. LEWIS, XIAOYUN WU, HEIDI GREULICH, MATTHEW MEYERSON, MANUEL ELLERMANN, PHILIP LIENAU, KNUT EIS, ANTJE MARGRET WENGNER, CHARLOTTE CHRISTINE KOPITZ, MARTIN LANGE
-
Publication number: 20180344739Abstract: The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of menorrhagia, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.Type: ApplicationFiled: August 10, 2018Publication date: December 6, 2018Inventors: Jorma HAßFELD, Tom KINZEL, Johannes KÖBBERLING, Yolanda CANCHO-GRANDE, Kristin BEYER, Susanne RÖHRIG, Maria KÖLLNBERGER, Michael SPERZEL, Nils BURKHARDT, Karl-Heinz SCHLEMMER, Christian STEGMANN, Joachim SCHUHMACHER, Matthias WERNER, Manuel ELLERMANN
-
Patent number: 10118930Abstract: The present application relates to novel substituted piperidinylpyrazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired hemostatic disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of heavy menstrual bleeding, postpartum hemorrhage, hemorrhagic shock, hemorrhagic cystitis, gastrointestinal hemorrhage, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.Type: GrantFiled: October 30, 2015Date of Patent: November 6, 2018Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Manuel Ellermann, Gaelle Valot, Yolanda Cancho Grande, Jorma Haßfeld, Tom Kinzel, Johannes Köbberling, Kristin Beyer, Susanne Röhrig, Michael Sperzel, Jan Stampfuß, Imke Meyer, Maria Köllnberger, Nils Burkhardt, Karl-Heinz Schlemmer, Christian Stegmann, Joachim Schuhmacher, Matthias Werner, Jörg Heiermann, Willem Jan Hengeveld
-
Patent number: 10098883Abstract: The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of menorrhagia, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.Type: GrantFiled: January 26, 2017Date of Patent: October 16, 2018Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Jorma Haßfeld, Tom Kinzel, Johannes Köbberling, Yolanda Cancho-Grande, Kristin Beyer, Susanne Röhrig, Maria Köllnberger, Michael Sperzel, Nils Burkhardt, Karl-Heinz Schlemmer, Christian Stegmann, Joachim Schuhmacher, Matthias Werner, Manuel Ellermann
-
Publication number: 20170334917Abstract: The present application relates to novel substituted piperidinylpyrazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired hemostatic disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of heavy menstrual bleeding, postpartum hemorrhage, hemorrhagic shock, hemorrhagic cystitis, gastrointestinal hemorrhage, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.Type: ApplicationFiled: October 30, 2015Publication date: November 23, 2017Applicant: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Manuel ELLERMANN, Gaelle VALOT, Yolanda CANCHO GRANDE, Jorma HAßFELD, Tom KINZEL, Johannes KÖBBERLING, Kristin BEYER, Susanne RÖHRIG, Michael SPERZEL, Jan STAMPFUß, Imke MEYER, Maria KÖLLNBERGER, Nils BURKHARDT, Karl-Heinz SCHLEMMER, Christian STEGMANN, Joachim SCHUHMACHER, Matthias WERNER, Jörg HEIERMANN, Willem Jan HENGEVELD
-
Publication number: 20170239251Abstract: The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of menorrhagia, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.Type: ApplicationFiled: January 26, 2017Publication date: August 24, 2017Inventors: Jorma HAßFELD, Tom KINZEL, Johannes KÖBBERLING, Yolanda CANCHO-GRANDE, Kristin BEYER, Susanne RÖHRIG, Maria KÖLLNBERGER, Michael SPERZEL, Nils BURKHARDT, Karl-Heinz SCHLEMMER, Christian STEGMANN, Joachim SCHUHMACHER, Matthias WERNER, Manuel ELLERMANN
-
Patent number: 9598417Abstract: The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of menorrhagia, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.Type: GrantFiled: November 5, 2014Date of Patent: March 21, 2017Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Jorma Haβfeld, Tom Kinzel, Johannes Köbberling, Yolanda Cancho Grande, Kristin Beyer, Susanne Röhrig, Maria Köllnberger, Michael Sperzel, Nils Burkhardt, Karl-Heinz Schlemmer, Christian Stegmann, Joachim Schuhmacher, Matthias Werner, Manuel Ellermann
-
Publication number: 20160280688Abstract: The invention relates to substituted phenylalanine derivatives and to processes for preparation thereof, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders and/or severe perioperative blood loss.Type: ApplicationFiled: September 24, 2014Publication date: September 29, 2016Applicant: Bayer Pharma AktiengesellschaftInventors: Ulrike RÖHN, Manuel ELLERMANN, Julia STRASSBURGER, Astrid WENDT, Susanne RÖHRIG, Robert Alan WEBSTER, Martina Victoria SCHMIDT, Adrian TERSTEEGEN, Kristin BEYER, Martina SCHÄFER, Anja BUCHMÜLLER, Christoph GERDES, Michael SPERZEL, Steffen SANDMANN, Stefan HEITMEIER, Alexander HILLISCH, Jens ACKERSTAFF, Carsten TERJUNG
-
Publication number: 20160280699Abstract: The invention relates to substituted phenylalanine derivatives and to processes for preparation thereof, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders and/or severe perioperative blood loss.Type: ApplicationFiled: September 24, 2014Publication date: September 29, 2016Applicant: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Ulrike RÖHN, Manuel ELLERMANN, Julia STRAßBURGER, Astrid WENDT, Susanne RÖHRIG, Robert Alan WEBSTER, Martina Victoria SCHMIDT, Adrian TERSTEEGEN, Kristin BEYER, Martina SCHÄFER, Anja BUCHMÜLLER, Christoph GERDES, Michael SPERZEL, Steffen SANDMANN, Stefan HEITMEIER, Alexander HILLISCH, Jens ACKERSTAFF, Carsten TERJUNG
-
Publication number: 20160272617Abstract: The invention relates to substituted phenylalanine derivatives and to processes for preparation thereof, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders and/or severe perioperative blood loss.Type: ApplicationFiled: September 24, 2014Publication date: September 22, 2016Applicant: Bayer Pharma AktiengesellschaftInventors: Ulrike RÖHN, Manuel ELLERMANN, Julia STRASSBURGER, Astrid WENDT, Susanne RÖHRIG, Robert Alan WEBSTER, Martina Victoria SCHMIDT, Adrian TERSTEEGEN, Kristin BEYER, Martina SCHÄFER, Anja BUCHMÜLLER, Christoph GERDES, Michael SPERZEL, Steffen SANDMANN, Stefan HEITMEIER, Alexander HILLISCH, Jens ACKERSTAFF, Carsten TERJUNG